David C Marek has sold MYOV and made no open-market buys since Jan 2022

Marek David C (commonly referenced as David C. Marek) is a biopharmaceutical executive and corporate insider who serves as Principal Executive Officer and board member of Myovant Sciences Ltd., while also holding the role of Chief Executive Officer of its operating subsidiary, Myovant Sciences, Inc.( He was appointed CEO of Myovant Sciences, Inc. in January 2021 and concurrently designated principal executive officer of Myovant Sciences Ltd., joining its board of directors at that time.( As of 2026, regulatory and insider-trading disclosures list him as the Principal Executive Officer of Myovant Sciences Ltd., reflecting his ongoing status as a key corporate insider at the company.(

Marek is a veteran biopharmaceutical and healthcare commercialization leader with more than 30 years of industry experience, including senior roles in pharmaceuticals, biotech, healthcare advertising, and digital health.( Before joining Myovant, he was Chief Commercial Officer at Axsome Therapeutics and previously General Manager of Amgen’s Neuroscience Business Unit, where he oversaw the successful U.S. launch and commercialization partnership for AIMOVIG, a first-in-class migraine preventive therapy, in collaboration with Novartis.( Earlier in his career, Marek served as Executive Vice President, Consumer Services at WebMD, leading a large multifunctional organization, and held global commercial leadership roles in launching and managing major pharmaceutical brands such as ENBREL, CRESTOR, ELOXATIN, SEROQUEL, and AMBIEN.( He later became Chief Executive Officer and Board Director of ReAlta Life Sciences, further underscoring his profile as a global healthcare CEO and board-level leader.( Marek holds a degree from Washington State University, where he completed his undergraduate education.(

Written by Perplexity from public sources.